Skip to main content
Feature Story

Cover Story: DisABLing imatinib

By Kai-Jye Lou, Senior Writer

DisABLing imatinib

Mutations in BCR-ABL tyrosine kinase have long been associated with resistance to Gleevec imatinib, but they only account for about half of all cases. University of Massachusetts researchers have shown that upregulation of protein kinase Ch could be an alternative cause and might provide a new target for bypassing resistance.1 But blocking the downstream signaling components could be easier than creating specific inhibitors of the relatively unexplored protein kinase C isoform.

Full Article

Today's Biotech & Pharma News

Chilling Reality

Subscribe Now
Free Trial

Preclinical Results